Finasteride has been FDA-approved for male pattern hair loss since 1997. It is the best-evidenced oral treatment available, full stop. This guide covers the science, the side effects (honestly — including the controversial ones), who it is right for, and where to get it.
Quick Answer
Finasteride 1mg daily stops further hair loss in approximately 90% of men and produces visible regrowth in approximately 65% at 12 months. It requires indefinite daily use to maintain results. Sexual side effects occur in 2-4% of men and are almost always reversible.
What Is Finasteride?
Finasteride is a 5-alpha reductase inhibitor. It was first approved by the FDA at 5mg (under the brand name Proscar) for benign prostatic hyperplasia (enlarged prostate) in 1992. The 1mg dose (Propecia) was approved specifically for androgenetic alopecia in men in 1997.
It is the only oral drug FDA-approved for male pattern hair loss.
How It Works: The DHT Mechanism
To understand finasteride, you need to understand DHT.
Dihydrotestosterone (DHT) is an androgen derived from testosterone. In men with the genetic predisposition to androgenetic alopecia, hair follicles on the scalp have receptors that are sensitive to DHT. When DHT binds to these receptors, the follicles undergo progressive miniaturization — they produce progressively finer, shorter hairs over years, eventually becoming vellus hairs (the fine, barely-visible kind) and then stopping production entirely.
The enzyme 5-alpha reductase catalyzes the conversion of testosterone to DHT. Finasteride inhibits this enzyme — specifically the type II isoform — reducing DHT levels in the scalp by approximately 70% and in the blood by approximately 60-70%.
By substantially reducing DHT levels, finasteride removes the primary driver of follicle miniaturization. Follicles that were miniaturizing stabilize and begin to recover. Over months to years, some follicles that had produced only fine hairs begin producing terminal hairs again.
Finasteride does not remove the genetic predisposition to hair loss. It manages the process by continuously suppressing DHT. This is why treatment must be continuous.
What Does the Research Say?
The evidence base for finasteride is extensive — 25+ years of post-approval real-world use combined with multiple randomized controlled trials.
The landmark Merck trials (1997-1999): In the pivotal trials that led to FDA approval, finasteride 1mg daily was compared to placebo in 1,879 men aged 18-41 with mild to moderate hair loss. At 12 months:
- 86% of men on finasteride maintained or increased hair count versus baseline
- 65% showed visible hair regrowth in global photographic assessment
- 14% showed improvement in hair count vs. placebo
- In the placebo group, 58% continued to lose hair
Long-term data: A 5-year extension study showed that 90% of men on finasteride maintained or improved their hair count. The drug does not stop working over time for the majority of users.
Combination therapy: A 2021 study in JAMA Dermatology showed that combination finasteride + minoxidil produced significantly better outcomes than either alone — approximately 94% of men showed improvement versus 80% for finasteride alone and 59% for minoxidil alone at 12 months.
Early treatment advantage: Finasteride is significantly more effective when started early — when follicles are miniaturizing but still producing some hair — compared to starting when significant baldness is already established. Follicles that have been completely dormant for many years are unlikely to be reactivated.
What Are the Side Effects?
The most complete and honest discussion of finasteride side effects acknowledges several realities:
Reported Sexual Side Effects
In the original Merck clinical trials, sexual side effects were reported in approximately 3.8% of men taking finasteride versus 2.1% in the placebo group — a statistically significant but modest difference. The specific effects reported were:
- Decreased libido
- Erectile dysfunction
- Decreased ejaculate volume
These occurred in a minority of users, and in the trials, they were reversible upon stopping treatment.
The Nocebo Effect and Context
An important complication in interpreting finasteride side effect data: the nocebo effect is well documented in finasteride studies. In a 2017 study, men who were told they might experience sexual side effects had significantly higher rates of reporting them than men who were not told.
This doesn't mean the side effects aren't real — they are real for many men. It means that the true incidence of physiologically drug-caused sexual dysfunction may be lower than some headlines suggest, because some reported cases reflect nocebo effects (anxiety about side effects causing the very symptoms).
A 2020 meta-analysis reviewed 34 randomized trials and found that sexual dysfunction attributable to finasteride was "relatively low and reversible in most cases."
Post-Finasteride Syndrome (PFS)
This is the controversial part, and we are going to be direct rather than dismissive.
Post-finasteride syndrome refers to a constellation of persistent symptoms — sexual dysfunction, depression, cognitive difficulties — that some men report experiencing after stopping finasteride, sometimes lasting months to years.
What we know: The Post-Finasteride Syndrome Foundation has documented thousands of cases. The FDA added a warning to finasteride labeling in 2012 acknowledging the possibility of persistent sexual side effects after discontinuation. A 2021 JAMA Dermatology review acknowledged that "a small subset of patients may experience prolonged sexual adverse events."
What is contested: The prevalence (estimates range from well under 1% to higher depending on study methodology), the mechanism, whether it is causally related to finasteride versus psychological factors or underlying predisposition, and how to treat it.
Our position: Post-finasteride syndrome is real for those who experience it, and anyone considering finasteride deserves to know it exists before starting. The risk appears low, but "low" is not zero, and for a cosmetic treatment (one being used for hair, not a life-threatening condition), the risk-benefit calculation is highly personal. We do not minimize this.
If you have pre-existing depression, anxiety, or sexual health concerns, discuss them with a doctor before starting finasteride.
Who Is Most at Risk
Research suggests men with pre-existing sexual dysfunction, depression, or high health anxiety may be at higher risk of experiencing finasteride side effects — both the physiological and nocebo-mediated variety. There is also emerging evidence that men with certain androgen receptor variations may be more susceptible.
Who It's For
Finasteride is well-suited for:
- Men aged 18-50 with early to moderate androgenetic alopecia — this is the population with the strongest evidence base
- Men who started losing hair in their 20s or 30s — early-onset hair loss tends to be aggressive without treatment
- Men who want the most effective single oral treatment available
- Men who understand the commitment — this is indefinite daily medication
Who Should Avoid It
- Men trying to conceive in the near future — finasteride does not reliably reduce sperm counts at 1mg, but there is some evidence of reduced semen parameters; discuss with a fertility specialist if trying to conceive
- Men with pre-existing sexual dysfunction who are not comfortable with additional risk
- Women who are pregnant or may become pregnant — contraindicated, causes birth defects
- Men with serious liver disease — finasteride is hepatically metabolized
- Men under 18 — not studied in this population
- Men with late-stage baldness in the affected areas — finasteride cannot regrow hair where follicles are no longer viable
Topical vs. Oral Finasteride
Topical finasteride is a newer formulation offered primarily through Hims and some compounding pharmacies. It is applied directly to the scalp in a liquid or gel vehicle.
The case for topical: Lower systemic absorption means lower systemic DHT reduction (around 20-30% versus 60-70% for oral). This means less exposure for any systemic side effects, including sexual dysfunction. For men concerned about the side effect profile, topical is a reasonable alternative.
The case for oral: Oral has the entire clinical evidence base behind it. Topical is newer, with less long-term data. The lower DHT reduction may mean somewhat lower efficacy. We don't yet have head-to-head 5-year data comparing topical to oral outcomes.
Current evidence: A 2021 RCT showed topical finasteride 0.25% solution applied once daily produced similar hair count improvements to oral at 24 weeks. Larger and longer trials are ongoing.
For men highly concerned about systemic side effects, topical is a reasonable choice. For most men, the well-established oral formulation is the standard starting point.
Where Can You Get Finasteride?
Telehealth platforms are the most practical option for most men. A prescription via telehealth avoids the need for an in-person dermatology appointment and costs significantly less than brand-name Propecia at a retail pharmacy.
The three we recommend:
- Keeps — best value for oral finasteride, around $25-35/month
- Hims — best option if you want topical finasteride specifically, or the combination topical spray
- Ro — competitive pricing, also offers compounded topical finasteride + minoxidil
See our detailed Hims vs. Keeps vs. Ro comparison for the full analysis.
In-person dermatology is appropriate if you have complex hair loss, unusual presentation, other health conditions that need consideration, or prefer the traditional care model.
Generic at a pharmacy: Generic finasteride 1mg is available at standard retail pharmacies with a prescription from any physician. GoodRx codes can bring the cost under $20/month. The telehealth platforms are often cheaper, but this is worth knowing.
What Should You Expect When Starting Treatment?
Month 1-3: No visible change. DHT is being suppressed, but follicles take time to respond. Some men experience an increase in shedding in the first few months as follicles reset — this is a positive sign, not a negative one.
Month 3-6: Shedding slows or stabilizes. Some men start to notice slightly thicker hair texture.
Month 6-12: Visible regrowth becomes noticeable for most responders. The hairline tends to respond less robustly than the crown and mid-scalp.
Month 12-24: Continued improvement is common. Take standardized photos monthly under the same conditions — the changes are gradual enough that unaided perception is unreliable.
12+ months (ongoing): Stable maintenance of results with continued treatment.
The Bottom Line
Finasteride 1mg daily is the most effective single oral treatment for male pattern hair loss with 25 years of evidence behind it. For men with early to moderate androgenetic alopecia who are committed to continuous treatment, it is the evidence-based first choice.
The side effect profile is real but modest for the majority of men, and almost entirely reversible on stopping. Post-finasteride syndrome is a rare but real phenomenon that deserves honest acknowledgment, not dismissal.
Finasteride combined with minoxidil is the most effective approach. Get both through a telehealth platform with physician oversight, track your progress with standardized photos, and give it 12 full months before drawing conclusions.
Sources
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Journal of the American Academy of Dermatology. 1998;39(4):578-589. PMID: 9777765.
- U.S. Food and Drug Administration. Propecia (finasteride 1mg) — NDA approval, 1997. FDA Drug Approvals and Databases.
- Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology. 2010;146(10):1141-1150. PMID: 20956647.
- Hu R, Xu F, Han Y, et al. Comparison of finasteride and minoxidil alone and in combination in treating male androgenetic alopecia: evidence from a meta-analysis. JAMA Dermatology. 2021;157(11):1365-1367. PMID: 34613349.
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017;77(1):136-141. PMID: 28366521.
- Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? Journal of Sexual Medicine. 2012;9(11):2927-2932. PMID: 22938876.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatology. 2022;158(3):266-274. PMID: 35080594.
We earn $40-80/signup if you sign up · See all commissions
We earn $50-100/signup if you sign up · See all commissions
We earn $40-80/signup from Keeps and $50-100/signup from Hims. Our methodology page explains our full affiliate disclosure. These commissions do not influence our clinical assessments.